AQP4 and neuromyelitis optica: The anti-AQP4 antibodies cannot induce disease development without pre-existing T-cell-mediated CNS inflammation and BBB disruption, as the injection of anti-AQP4 antibodies alone from the periphery is not sufficient to mediate NMO-like histopathology [137,138].